|Day Low/High||2.45 / 2.56|
|52 Wk Low/High||0.20 / 0.64|
TheStreet's biotech columnist offers his own report card on biotech stocks.
Long-Term Survival Data Reported from Phase 1 ICT-107 Trial
Solution enhances global supply chain management of biologic commodities
Over 100 Patients Screened in Phase 3 ICT-107 Trial in Newly Diagnosed Glioblastoma;
A defrocked analyst brushes off the serious problems weighing on Northwest Bio. Instead, he jacks the tired 'blame the shorts' excuse to another level.
Data support phase 3 registration trial incorporating key design modifications to potentially optimize outcomes
ICT-107 Phase 3 Trial on Track to Begin in Fourth Quarter
Mr. Schlossberg and Mr. Lapointe Will Serve as Independent Members of the Board of Directors